First Clinical Data on Ornithine Transcarbamylase Deficiency Program presented at the European Society of Gene & Cell Therapy 31st Annual Meeting 2024 Demonstrates Curative Potential in First Patient Treated

London, UK, 24 October 2024 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today announced that clinical data for BGT-OTCD, the Company’s AAV-LK03 gene therapy candidate for the treatment of ornithine transcarbamylase deficiency […]

Read more

First Clinical Data on Ornithine Transcarbamylase Deficiency Program to be presented at the European Society of Gene & Cell Therapy 31st Annual Meeting 2024

London, UK, 01 October 2024 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today announced that clinical data for BGT-OTCD, the Company’s AAV-LK03 gene therapy candidate for the treatment of ornithine transcarbamylase deficiency […]

Read more

Bloomsbury Genetic Therapies Showcases its First Preclinical Data on Parkinson’s Disease Program at the American Society of Gene & Cell Therapy 2024 Annual Meeting

London, UK, 9 May 2024 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today presented new preclinical data on its gene therapy candidate, BGT-PD, in a poster presentation at the 27th Annual Meeting […]

Read more

First Preclinical Data on Parkinson’s Disease Program to be presented at the American Society of Gene & Cell Therapy 27th Annual Meeting 2024

London, UK, 03 April 2024 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today announced that new preclinical data supporting BGT-PD, the Company’s AAV2 gene therapy candidate for the treatment of levodopa-induced dyskinesia […]

Read more

Bloomsbury Genetic Therapies Announces Initiation of Recruitment in Phase 1/2 HORACE Clinical Trial of Investigational Gene Therapy BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)

– HORACE trial initiated to evaluate the safety, efficacy and tolerability of BGT-OTCD in paediatric patients diagnosed with OTCD –   London, UK, 16 November 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, […]

Read more

Bloomsbury Genetic Therapies Celebrates its One Year Anniversary and Outlines Key Strategic and Operational Achievements since Launch

London, UK, 13 November 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, is proud to celebrate its one-year anniversary. Since its official launch last October with £5 million in Seed funding, the Company […]

Read more

Bloomsbury Genetic Therapies Receives Orphan Drug Designations from the European Commission and the US FDA for BGT-INAD for the Treatment of Infantile Neuroaxonal Dystrophy and Provides Update on Type B Pre-IND Meeting with the US FDA

– Type B pre-IND meeting with the US FDA provides detailed advice on the Company’s CMC, non-clinical and clinical development plans for BGT-INAD –   London, UK, 23 October 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically […]

Read more

Bloomsbury Genetic Therapies Receives Orphan Drug Designations from the European Commission and the US FDA for BGT-NPC for the Treatment of Niemann-Pick Disease Type C and Provides Update on Type B Pre-IND Interaction with the US FDA

– Type B pre-IND interaction with the US FDA provides constructive feedback on the Company’s CMC, non-clinical and clinical development plans for BGT-NPC –   London, UK, 17 October 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically […]

Read more

Bloomsbury Genetic Therapies Announces Recent Publication of Three Articles Supporting the Preclinical Efficacy and Differentiation of BGT-OTCD as a Potential Treatment for Ornithine Transcarbamylase Deficiency (OTCD)

London, UK, 18 September 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, announced today the recent publication of three research articles supporting the preclinical efficacy and differentiation of BGT-OTCD as a potentially curative […]

Read more

Bloomsbury Genetic Therapies Announces New Program in Parkinson’s Disease

London, UK, 6 September 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, is pleased to disclose its new pipeline program BGT-PD, an investigational gene therapy candidate for Parkinson’s disease (PD). BGT-PD is an […]

Read more